Why ASX private health shares aren't as good as they look

Here's why I don't like the future prospects of ASX private health stocks like Medibank Private Ltd (ASX: MPL)

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

From my humble observations, Australians seem to enjoy a love/hate relationship with private health insurance. It's always nice flashing your card when you visit the dentist or physio, but paying those weekly or monthly premiums is a bit of a hassle (to put it mildly).

What's more, private health premium costs are one of those things that just seem to keep on rising – usually well above inflation and the cost of living as well.

So with that in mind, you would think private health is a ripe place to invest these days. The sector enjoys widespread use and acceptance as a 'backup' to the publicly funded Medicare. Not only that, there are significant government incentives for individuals (particularly on higher incomes) to take out private health insurance – along with penalties for those who don't.

Most companies don't enjoy that kind of public assistance – in fact, having the government herd customers into your arms is something most businesses can only dream of. Reviewing the performance of the ASX's 2 largest private health insurers, it looks on first glance as though private health is a no-brainer.

Medibank Private Ltd (ASX: MPL) shares have only been on the public markets since its privatisation in 2014 at around $2 per share. Today, MPL shares are going for $3.36 (at the time of writing) and come with a 3.88% dividend yield. A dividend yield that has been steadily increasing since 2014 to boot!

It's a similar story with NIB Holdings Limited (ASX: NHF). NHF shares were asking around $1.30 10 years ago, but today will set you back $6.92, with a 3.89% dividend yield. NIB's dividend payouts have also been steadily increasing over the past decade.

a woman

The problem with private health

Before you get the cheque book out, I think it's worth noting that past performance is no indication of the future. As a matter of fact, I believe that things aren't looking so rosy from here.

We have a rapidly ageing population in Australia, which means that over time there will be less healthy, younger people to pay for the higher medical needs of the older generations.

That means rising premiums.

Rising premiums in turn mean there is less incentive for younger people to take out the health insurance in the first place. This has the potential to become a vicious cycle for the fund providers, if it isn't happening already.

Foolish takeaway

Whilst I love both Medibank's and NIB's management and past performance, I think there are significant structural issues for this space as a whole going forward. These issues make me disinclined to pursue this industry for my own portfolio – at least until I can see a clearer path towards the system's sustainability.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »